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Replacement after Adrenalectomy
Masahiro Inoue, Hisamitsu Ide, Koji Kurihara, Tatsuro Koseki, Jingsong Yu, Toshiyuki China, 
Keisuke Saito, Shuji Isotani, Satoru Muto, Shigeo Horie
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan
Purpose: The purpose of this study was to investigate the clinical and hormonal features 
of patients with incidentally discovered adrenal adenomas in relation to corticotropin 
releasing hormone (CRH) testing and the clinical outcome of adrenalectomy. 
Materials and Methods: Twenty-three consecutive patients with incidentally detected 
adrenal adenomas were included in this retrospective study. All the patients under-
went abdominal computed tomography scans and hormonal assays, including assess-
ment of circadian rhythms of plasma cortisol and corticotropin (adrenocorticotropic 
hormone, ACTH), a corticotropin stimulation test, and low-dose and high-dose dex-
amethasone tests. The patients were reevaluated at regular intervals (6, 12, and 24 
months) for a median period of 24 months. Subclinical Cushing’s syndrome (SCS) was 
diagnosed in patients with subtle hypercortisolism who did not present clinical signs 
of Cushing’s syndrome. 
Results: We calculated the responsive index (peak value of ACTH in CRH test/baseline 
value of ACTH in CRH test). Of 23 patients, 6 had Cushing’s syndrome, 8 had SCS, 
and 9 had a non-functioning tumor. All patients underwent laparoscopic adrenalec-
tomy. Several patients (5 of 6 with Cushing’s syndrome and 2 of 8 with SCS) required 
cortisol replacement therapy after surgery. The remaining patients required no hormo-
nal replacement after surgery. Those who required hormone replacement had a re-
sponsive index of less than 1.2. Those who did not need hormone replacement therapy 
had a responsive index of more than 2.0. 
Conclusions: In our limited experience, the responsive index of the CRH test might be 
a valuable tool for predicting the need for cortisol replacement after surgery in patients 
with SCS.
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INTRODUCTION
Subclinical Cushing's syndrome (SCS) is defined as auton-
omous cortisol secretion in patients who do not have the 
typical signs and symptoms of hypercortisolism. To screen 
for adrenal autonomy, an overnight dexamethasone (DEX) 
(1 mg) suppression test is currently recommended for pa-
tients with adrenal incidentaloma [1,2]. In a meta-analysis 
of 13 studies, including 2,005 patients with adrenal in-
cidentalomas, autonomous cortisol secretion occurred in 
5% of the patients [3]. Chronic, mild, endogenous cortisol 
excess in SCS patients may have important systemic ef-
fects on the human body. Although the obvious symptoms 
of Cushing's syndrome (CS) are absent, SCS patients have 
a higher risk of cardiovascular disease, obesity, diabetes 
mellitus, and osteoporosis [4-8]. Currently, there is no con-Korean J Urol 2012;53:414-418
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sensus on the optimal management of SCS. Adrenalectomy 
may reduce the cardiovascular risk profile [8]; therefore, 
consideration of surgical treatment for younger patients 
and for those with disorders that may be attributed to au-
tonomous glucocorticoid secretion may be reasonable. 
Patients with SCS should receive perioperative replace-
ment of glucocorticoids because they are at risk for hypoa-
drenalism after removal of the functioning mass. They 
should be monitored for subsequent hypothalamic-pitui-
tary-adrenal (HPA) axis recovery and clinical improve-
ment [2,9]. However, guidelines for follow-up of those pa-
tients who have undergone resection have not been 
defined. The need for longer-term replacement and taper-
ing of exogenous glucocorticoids has been assessed post-
operatively in an empirical manner.
The corticotropin releasing hormone (CRH) test has 
been widely used as a noninvasive tool in the differential 
diagnosis of corticotropin (adrenocorticotropic hormone, 
ACTH)-dependent CS [10]. Following administration of 
CRH, most patients with pituitary-dependent CS show a 
rise in plasma ACTH and cortisol, usually to a peak level 
greater than that in normal subjects, whereas those with 
non-pituitary sources of ACTH do not. In typical CS with 
cortisol-producing adrenal adenomas, administration of 
CRH does not stimulate the production of ACTH. However, 
the response to the CRH test in SCS has not been reported. 
The purpose of the present study was to evaluate the pres-
ence of SCS in a group of consecutive patients with in-
cidentally discovered adrenal adenomas and to examine 
whether the CRH test could predict the need for lon-
ger-term exogenous glucocorticoids after adrenalectomy.
MATERIALS AND METHODS
1. Patients
From 2003 to 2006, 23 consecutive patients (15 women and 
8 men; age range, 20 to 72 years; mean, 51.5 years) with 
incidentally detected adrenal masses who were referred 
from several hospitals underwent laparoscopic adrenalec-
tomy at Teikyo University Hospital. All incidentalomas 
were discovered by abdominal ultrasound or computed to-
mography (CT) scans performed for the evaluation of un-
related diseases or annual health checkups. None of the pa-
tients had extraadrenal malignancies, hypertension, or 
hyperglycemia of possible endocrine origin. No patient 
showed signs or symptoms of hormone production excess, 
and no patient was on any kind of hormonal therapy.
2. Preoperative evaluations
For blood chemistry and hormonal analyses, all patients 
were hospitalized 2 to 3 months before surgery to reduce 
the psychological stress that potentially alters the hormo-
nal profiles. All patients underwent the following endo-
crine evaluation: baseline serum cortisol (F) and plasma 
ACTH at 0800, 1600, and 2400 hours (mean of at least 2 
samples taken on different days); lutenizing hormone 
(LH), follicle stimulating hormone (FSH), and testoster-
one; and a low-dose 1-mg dexamethasone (DXM) sup-
pression test (orally, 0.5 mg, twice a day for 2 days, with 
measurement of serum cortisol and other steroids at 0800 
hours the following morning). Pheochromocytomas were 
excluded by measuring the 24-hour urinary excretion of 
catecholamines and vanillylmandelic acid. Plasma renin 
activity and serum levels of aldosterone in the upright pos-
ture were measured to exclude aldosterone-producing 
adenomas. The response of the pituitary-adrenal axis to 
exogenous CRH was assessed by using human CRH (100 
μg intravenously at 0900). The serum levels of ACTH were 
measured before injection and at 15 minutes, 30 minutes, 
60 minutes, and 90 minutes after injection. The responsive 
index was defined as the peak value of ACTH after in-
jection/baseline ACTH value 100 (%). A high-dose DXM 
test was performed (2 mg, 4 times a day for 2 days) if the 
patient had not responded to the low-dose DXM sup-
pression test. F circadian rhythm abnormalities were eval-
uated by calculating the F fraction as (F 2400/f 0800)×100. 
SCS was diagnosed according to the recommendations of 
the annual report of the research committee of “disorders 
of adrenal hormones” that is sponsored by the Ministry of 
Health and Welfare Japan [11]. The criteria, in addition to 
the presence of an adrenal mass and a lack of overt signs 
and symptoms of CS, for the diagnosis of SCS are as follows: 
1) normal baseline of serum cortisol, 2) autonomy of cortisol 
secretion tested by 1 mg of DEX administration, 3) sup-
pressed levels of plasma ACTH, 4) isotope uptake by the 
affected site of the adrenal gland, but not by the con-
tralateral site as assessed by adrenal scintigraphy, 5) lack 
of diurnal rhythm of plasma cortisol levels, 6) low level of 
serum dehydroepiandrosterone-sulfate (DHEA-S), and 7) 
transient adrenal insufficiency or the atrophy of the re-
sidual normal adrenal after removal of the adrenal tumor. 
Conditions 1) and 2) are both essential with at least 1 addi-
tional positive finding for conditions 3) to 7) required for the 
diagnosis of SCS.
3. Laparoscopic adrenalectomy
All laparoscopic procedures were done with the patient un-
der general anesthesia by use of the transperitoneal ante-
rior approach as described elsewhere [12]. In a patient with 
bilateral asymmetric adrenal tumors, the adrenal gland 
with a dominant tumor was resected.
4. Postoperative follow-up
All patients were evaluated on the same schedule for a me-
dian period of 24 months. Serum levels of cortisol and 
ACTH were measured every 3 months. If clinical symptoms 
of cortisol deficiency were noted, an appropriate dose of cor-
tisol was supplemented. A CRH test was done every 3 or 
6 months. Abdominal CT scans were done 6 months and 12 
months after the operation. None of the patients developed 
clinical signs of hormonal excess during the follow-up 
period. Women of reproductive age were studied in the ear-
ly follicular phase of the menstrual cycle (days 3 to 6).Korean J Urol 2012;53:414-418
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5. Corticoadrenal scintigraphy
Corticoadrenal scintigraphy was performed by using 
[
75Se]selenio-6α-methyl-19-nor-cholesterol (Scintadren, 
Amersham Pharmacia Biotech, Amersham, The Nether-
lands) in 14 patients. Scintigrams were obtained by crystal 
γ-camera 7 days after radiotracer injection. All scintiscans 
were reviewed by the same operator.
6. Endocrinological tests
All hormone assays were performed in the same laboratory 
by using commercially available kits. F was measured by 
a solid-phase chemiluminescent enzyme immunoassay 
and ACTH was tested by double-antibody 
125I radioim-
munoassay.
7. Statistical analysis
Analysis of variance was used for comparison of mean hor-
mone levels between groups. The nonparametric method 
(Mann-Whitney U-test) was used when the data were not 
distributed in a Gaussian manner. p＜0.05 was considered 
significant.
RESULTS
1. Clinical data
Patients (n=23; 8 men and 15 women; 20 to 72 years old; 
mean age, 51.5 years) with adrenal incidentaloma were in-
cluded in this study (Table 1). In 10 patients, the tumors 
were located on the left side; in 13, they were on the right 
side. One patient presented with bilateral masses. 
According to the CT scans, the sizes of the tumors ranged 
from 2.6 to 140 ml. CS was diagnosed in 6 patients, SCS was 
diagnosed in 8, and nonfunctioning adrenal tumors were 
found in the other 9. The median tumor size was sig-
nificantly larger in patients with nonfunctioning tumors 
than in patients with CS or SCS. All 6 CS patients, 6 of 8 
SCS patients, and 3 of 9 nonfunctioning tumor patients 
were female. Three patients with CS and 2 patients with 
SCS had mild to severe hypertension, 2 patients with CS 
and 1 patient with SCS had type 2 diabetes with fasting hy-
perglycemia (＞120 mg/dl), and 3 patients with CS, 4 pa-
tients with SCS, and 5 patients with nonfunctioning tu-
mors were diffusely obese (body mass index＞25).
2. Corticoadrenal scintigraphy
No uptake of radioisotope was seen in patients with a non-
functioning tumor. Radioisotope uptake was bilateral and 
predominant on the left side in the 1 patient with a bilateral 
adrenal tumor (CS-5) and was asymmetrical and prevalent 
on the side of the lesion in 4 CS patients and 6 SCS patients.
3. Endocrine data
Mean baseline cortisol measured at 0900 was 24.4 μg/dl 
(range, 16.8 to 36.2 μg/dl) in the CS patients, 13.3 μg/dl 
(range, 9.1 to 18.6 μg/dl) in the SCS patients, and 12.4 μg/dl 
(range, 3.6 to 22 μg/dl) in the patients with non-functioning 
tumors. Baseline cortisol levels were significantly higher 
in the CS patients than in the patients with SCS or non-
functioning tumors (p=0.02 and p=0.02, respectively). 
Circadian rhythm was not detected in any CS patients, but 
was noted in 2 of 8 SCS patients and in 1 of 8 patients with 
a non-functioning tumor. All patients with CS showed no 
suppression in either the low-dose (1 mg) or the high-dose 
(8 mg) DXM suppression tests. Low-dose DXM did not sup-
press serum cortisol levels in any patient with SCS. 
Low-dose DXM suppressed the serum cortisol levels in all 
patients with non-functioning tumors.
No response was observed in ACTH values with the CRH 
test in any CS patients. Of the 6 patients with SCS, 2 
showed minor responses (responsive index, 1.0 and 1.2) 
and 4 showed higher responses to the CRH test (responsive 
index, 2.0 to 17.4). Patients with a nonfunctioning tumor 
showed responses to the CRH test with a responsive index 
between 2.8 and 8.5 (Table 1).
All patients underwent laparoscopic adrenalectomy. 
The histological diagnosis was cortical adenoma in all cases. 
After surgery, all CS patients and 2 SCS patients needed cor-
tisol replacement therapy for adrenal insufficiency. The re-
sponsive indexes in their CRH tests were less than 1.2. The 
other 16 patients, whose responsive indexes varied be-
tween 2.0 and 17.4, did not require cortisol supplementa-
tion after the operation.
DISCUSSION
The term adrenal incidentaloma refers to an adrenal mass 
that is unexpectedly detected through an imaging proce-
dure done for reasons a priori unrelated to adrenal dysfunc-
tion or suspected dysfunction [13]. Adrenal incidentalomas 
are typically detected during ultrasonography, CT scan-
ning, or magnetic resonance imaging. Although these tech-
niques permit a diagnosis without further evaluation, it is 
important to recognize that imaging results may not be de-
finitive in any individual case. Surgery is the ultimate sol-
ution for the diagnostic-therapeutic dilemma of adrenal 
incidentaloma. However, there is insufficient evidence for 
the usefulness of surgical treatment in SCS patients to rec-
ommend it for all of them. Previous data about the effects 
of SCS and its natural history are still unclear. The problem 
is that the follow-up periods of such patients in various 
studies have been relatively short. For this reason, in our 
study, we estimated the tumor size by CT scan before sur-
gery and surgical treatment was restricted to patients with 
larger tumors. Several reports suggest that 12 to 16% of pa-
tients with adrenal incidentaloma have some form of sub-
clinical abnormalities in the HPA axis, designated as SCS 
[14-18]. Recent literature shows that patients with SCS 
may represent a population at higher risk for metabolic dis-
orders and cardiovascular disease [4-8]. Laparoscopic sur-
gery has made adrenalectomy a less invasive treatment, 
although the necessity for steroid supplementation could be 
a further burden for patients with adrenal incidentalomas. 
Patients with subclinical hypercortisolism should receive 
perioperative glucocorticoids because they are at risk for Korean J Urol 2012;53:414-418
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hypoadrenalism after removal of the functioning mass. 
They should be monitored for subsequent HPA axis recov-
ery and clinical improvement, which requires regular vis-
its to the ambulatory clinic. Thus, the probability of neces-
sary postoperative steroid supplementation should be ex-
plained at the time of obtaining informed consent for the 
operation. However, predicting which patients will need 
glucocorticoid replacement therapy after surgical treat-
ment of the adrenal adenoma is not an easy task. Several 
lines of evidence suggest that radiocholesterol uptake re-
flects the functional characteristics of adrenocortical 
lesions. In a recent study, adrenal scintiscans were per-
formed in 136 patients affected by adrenal incidentaloma, 
indicating a significant positive correlation between ab-
normalities in the cortisol secretion rate and radiotracer 
uptake [19]. However, Rossi et al. [6] argued that the scinti-
graphic pattern of the uptake of radiocholesterol is not ef-
fective for predicting adrenocortical insufficiency after 
surgical treatment. They demonstrated that preoperative 
abnormalities in cortisol production are not reliable in pre-
dicting which patients will need glucocorticoid replace-
ment therapy after surgical treatment of the adenoma. 
Thus, they propose that all patients who undergo adrena-
lectomy should be screened for residual adrenal function 
[6].
The CRH test is in widespread use for the differential di-
agnosis of ACTH-dependent CS [10]. It is also useful for 
monitoring the postoperative restoration of the suppressed 
pituitary-adrenal function in CS [20].
In our limited experience, SCS patients whose re-
sponsive index was ＜2.0 required steroid supplementa-
tion after adrenalectomy. To our knowledge, this is the first 
report to show that the responsive index obtained by the 
preoperative CRH test could be used to predict the post-
operative need for hormonal replacement in SCS. Further 
study is necessary to confirm the usefulness of this index.
CONCLUSIONS
The responsive index (peak value of ACTH in CRH 
test/baseline value of ACTH in CRH test) of the CRH test 
might be an effective tool for predicting the need for cortisol 
replacement after surgery in SCS patients.
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